Product Images Doxorubicin Hydrochloride

This is a description of a medication called DOXOrubicin Hydrochloride Liposome Injection which comes in a 20 mg/10 mL single-dose vial. It is designed for intravenous infusion only and should be discarded if any amount goes unused. The formulation should be kept in the refrigerator at a temperature range of 2 10.8°C (36° 10 46°F). The medication is packaged and distributed by Northstar Rx LLC in Memphis, TN. The product contains PEGHLATED Iposoma crrrs aro which is composed of cholesterol, Incrogenated soyphosphatyichlne (HSPD), carbory-mathaypolotylorogycd 2000712 distaarylsghcaro3 phosphothanok, and PEG-DSPE. The regular dosage and dilution requirements of the medication are stated on the packaging.*

DOXOrubicin Hydrochloride Liposome Injection is a liposomal formulation that should not be substituted for DOXORUBICIN HCL. It is available in a single-dose vial which must be discarded if unused. This drug is meant for intravenous infusion only and must be diluted before administration. Each mL of the injection contains USP doxorubicin HC, 2mg, and PEGYLATED liosome carriers composed of cholesterol, fully hydrogenated soy phosphatidyichaline, and M-{carbonyl-methocypolyethylene gycol 200012 distearoyksn-giycero-3 phosphoethanak amine sodium salt. The injection also contains ammonium sulfite, sucrose, histidine, and hydrochloric acid and/or sodium hydroxide. The drug should be refrigerated between 2°10 8°C (36° to 46°F) and not frozen. The package insert should be consulted for dosage information. The drug is sterile and must be kept out of reach of children. This formulation of DOXOrubicin Hydrochloride Liposome Injection is manufactured by Natco Pharma Ltd in India and distributed by Northstar Rx LLC in Memphis, TN.*

This appears to be a product label or packaging information for a medication called "DOXOrubicin Hydrochloride Liposome injection". The medication is meant for intravenous infusion and comes in a 50mg/25mL dose. It seems to be a substitute for another medication called "DoRoRUBICIN". The label also contains a lot number ("NOC terie 85601") and some safety instructions ("FOR INTRAVENOUS INFUSION ONLY").*

This looks like a chart or graph with statistical data related to the drugs Doxorubicin Hydrochloride and Bortezomib. The results suggest that Bortezomib may have a significant impact on reducing the risk of the condition being studied. However, there is not enough context to determine what the condition is or what the significance of the results mean.*